CD11b agonism overcomes PDAC immunotherapy resistance.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Targeting Triple NK Cell Suppression Mechanisms: A Comprehensive Review of Biomarkers in Pancreatic Cancer Therapy.International journal of molecular sciences · 2025
   Review
2. Interventional hydrogel microsphere vaccine as an immune amplifier for activated antitumour immunity after ablation therapy.Nature communications · 2023
   Article
3. Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance.Cancer metastasis reviews · 2021
   Review

Corrections and comments

• Comment on
  Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies.2019

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as